# A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

> **NCT06932562** · PHASE3 · RECRUITING · sponsor: **European Myeloma Network B.V.** · enrollment: 1000 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Linvoseltamab
- **DRUG:** Daratumumab
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT06932562
- **Lead sponsor:** European Myeloma Network B.V.
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-23
- **Primary completion:** 2036-12
- **Final completion:** 2036-12
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2026-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06932562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06932562, "A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT06932562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*